EORTC-1525-LCG: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)
The Nivothym study is a clinical trial exploring new treatment options for people with a rare form of cancer called type B3 thymoma or thymic carcinoma. These cancers affect the thymus gland, located in the chest. This study focuses on patients whose cancer has already been treated with chemotherapy but has either returned or continued to grow. Researchers are testing two specific medications, ipilimumab and nivolumab, to see how well they work. These drugs are a type of immunotherapy, which helps your body's own immune system fight cancer. The main aim of the study is to find out if these medicines can stop the cancer from getting worse for at least six months. They will also look at how safe the treatments are, if the cancer shrinks, and how long people live after treatment.
At a glance
What is this study about?
This study, called Nivothym, is looking into new ways to treat a specific type of cancer that affects a small gland in your chest called the thymus. This gland is part of your immune system. The cancers the study is focusing on are called type B3 thymoma and thymic carcinoma. These are rare cancers, and doctors are always looking for better treatments.
You might be interested in this study if you've already had chemotherapy for your thymoma or thymic carcinoma, and the cancer has started to grow again or has come back. The study is testing two medications, ipilimumab and nivolumab. These are not traditional chemotherapy drugs; they are a type of treatment called immunotherapy. Immunotherapy works by boosting your body's own immune system to help it recognise and fight cancer cells more effectively. Researchers hope that these new treatments could offer a different and effective option for patients.
The main goal is to see if people taking these medicines can keep their cancer from getting worse for at least six months. This is an important step in finding out if these treatments are helpful. The study will also carefully check for any side effects and see if the cancer shrinks in some patients. All this information helps doctors understand if these new drugs could become standard treatment options in the future.
Key takeaways
- Tests new immunotherapy drugs (ipilimumab, nivolumab) for rare thymoma/thymic carcinoma.
- For patients whose cancer grew or returned after chemotherapy.
- Aims to see if cancer is stable for at least 6 months.
- Participants will have regular scans and blood tests.
- You can stop participating at any time.
Who may be eligible?
To join the Nivothym study, you need to be at least 18 years old. There's no upper age limit, so people of all adult ages can be considered. The study is open to both men and women.
The most important thing is that you must have a diagnosis of type B3 thymoma or thymic carcinoma. Also, these cancers must have been previously treated with chemotherapy and then either started growing again or not responded to the chemotherapy. This means the study is for patients whose cancer is proving challenging to treat with standard methods.
There might be other specific health requirements or conditions that would mean you can't join the study, even if you meet these main points. These are checked carefully by the study doctors to make sure the treatment is safe for you and that the study results will be clear.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with type B3 thymoma or thymic carcinoma?
- Has your cancer been treated with chemotherapy before?
- Has your cancer come back or grown after that chemotherapy?
What does participation involve?
If you decide to take part in the Nivothym study, you'll be given the study medications, ipilimumab and nivolumab. You'll have regular appointments at the hospital or clinic. These visits will involve blood tests, physical examinations by a doctor, and special scans (like CT or MRI scans) to see how the cancer is responding to the treatment.
These scans will be done regularly, for example, every few months, to check if the cancer is stable, getting smaller, or growing. You'll also be asked about any side effects or changes you notice in your health. The duration of the treatment will depend on how you respond and how you tolerate the medicines. Even after you stop the treatment, you'll likely have follow-up visits to monitor your health over time. The study will last for as long as you are benefiting from the treatment and for a follow-up period afterwards, which can be several years.
Potential risks and benefits
Locations (4)
- —UnverifiedBelgium
- —UnverifiedSpain
- —UnverifiedNetherlands
- —UnverifiedFrance
Common questions
What is the main goal of the Nivothym study?
The main goal is to see if the cancer stays stable for at least six months after treatment with the new medications.
What type of cancer is this study for?
It's for specific types of rare immune system cancers called type B3 thymoma and thymic carcinoma.
What are ipilimumab and nivolumab?
They are a type of treatment called immunotherapy, which helps your body's immune system fight cancer.
Do I have to have had chemotherapy before?
Yes, this study is for patients whose cancer has come back or grown after having chemotherapy previously.
Will I know if the treatment is working?
Yes, you will have regular scans and check-ups, and the study team will discuss the results with you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.